Dear Dr Pemberton,

Please find our revised version of the manuscript "Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemotherapy (HIPEC) in experimental investigations.."
MS: 4726153589009844 by Pelz et al. for reconsideration for publication in BMC Cancer. We have provide a point-by-point response below to the concerns of the two reviewers.

The difference of this paper from my previously accepted article in BMC Cancer (5:56) is:
1) Two more groups (shame operation and hyperthermic therapy alone)
2) The histological outcome of these five groups
3) BMC Cancer (5:56) is an methodic paper this abstract is a paper about histological outcome after different treatments.

The first article is a methodic paper which described the new animal model for hyperthermic intraperitoneal chemoperfusion (HIPEC) in rats. The important aspect was the possibility of inducing a limited peritoneal carcinomatosis model and the possibility of perfusion and the stress for the animals and safety of this method.

The first clinical datas were a forward look. This was the reason why hyperthermic only was not performed. BMC Cancer (5:56) was a basic research paper.

In contrast this paper shows the histological outcome of the treatment groups. The important detail is the difference between the clinical and the histological outcome. This is the reason for performing group III (hyperthermia only). It is very important to have a look to the histological side, because in human HIPEC histological examination is not possible.

We feel that the revisions have strenghtened the contention. The authors thank for your consideration of our revised manuscript.

Sincerely,

Joerg O.W. Pelz M.D.